IGA

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
People, Eye, Allergic conjunctivitis, Select, Anatomy, ATC, Safety, European Medicines Agency, Ageing, International, IGA, INN, Disease, Language, Overview, Dry, Patient, IIA, Thigh, Conjunctivitis, Marketing, EASI, Atopic dermatitis, Medical Subject Headings, Diagnosis, Red, Skin, Human, Inflammation, Instrumentation, Medicinal plants, Medical device, Copper, Vaccine, Medical imaging, Online shopping, Bookkeeping, Dermatitis, Medicine

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Swiss Red Cross Selects Omada Identity Cloud for SaaS IGA Provider

Retrieved on: 
Wednesday, December 13, 2023
Cloud, Organization, Swiss Red Cross, IGA, Red, CIO, Identity Governance Framework, Automation, Software as a service, Administration, Online shopping

COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced the Swiss Red Cross will use Omada Identity Cloud to manage its 2,400 identities, streamline identity automation and address compliance now and into the future.

Key Points: 
  • COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced the Swiss Red Cross will use Omada Identity Cloud to manage its 2,400 identities, streamline identity automation and address compliance now and into the future.
  • The Swiss Red Cross needed a way to ensure the requirements of data protection and information security were met and remained consistent in the future.
  • By deploying Omada Identity Cloud, Omada's highly scalable and performant software-as-a-service (SaaS) solution, the Swiss Red Cross will benefit from efficient onboarding, quality connectivity, audit and compliance reporting support, right out of the box.
  • We appreciate the close collaboration with SECURIX, which has been instrumental in enabling the Swiss Red Cross to successfully implement a secure and user-friendly identity management solution to manage identities with ease."

Swiss Red Cross Selects Omada Identity Cloud for SaaS IGA Provider

Retrieved on: 
Wednesday, December 13, 2023
Cloud, Organization, Swiss Red Cross, IGA, Red, CIO, Identity Governance Framework, Automation, Software as a service, Administration, Online shopping

COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced the Swiss Red Cross will use Omada Identity Cloud to manage its 2,400 identities, streamline identity automation and address compliance now and into the future.

Key Points: 
  • COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced the Swiss Red Cross will use Omada Identity Cloud to manage its 2,400 identities, streamline identity automation and address compliance now and into the future.
  • The Swiss Red Cross needed a way to ensure the requirements of data protection and information security were met and remained consistent in the future.
  • By deploying Omada Identity Cloud, Omada's highly scalable and performant software-as-a-service (SaaS) solution, the Swiss Red Cross will benefit from efficient onboarding, quality connectivity, audit and compliance reporting support, right out of the box.
  • We appreciate the close collaboration with SECURIX, which has been instrumental in enabling the Swiss Red Cross to successfully implement a secure and user-friendly identity management solution to manage identities with ease."

Ideal™ Digital Circular Surpasses 10,000 Stores Upgrading to the Digital Marketing Platform

Retrieved on: 
Wednesday, December 6, 2023
Ideal, Public key certificate, AWG, Entrepreneurship, ShopRite, IGA, MDI, Fast-moving consumer goods, Marketing, EVP, Gelson, CPG, Design House Stockholm, UNFI, Strack & Van Til, Retail, Sales

CLEVELAND, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Ideal™ by Design House announces a groundbreaking achievement as they surpass the milestone of 10,000 stores participating in their revolutionary Ideal™ digital circular. This comprehensive digital network spans across multiple grocery and hardware chains, revolutionizing digital advertising strategies and paving the way for enhanced customer engagement.

Key Points: 
  • This comprehensive digital network spans across multiple grocery and hardware chains, revolutionizing digital advertising strategies and paving the way for enhanced customer engagement.
  • The Ideal digital circular has evolved into an extensive network, serving national and regional chains, including Coborn's, Gelson's, Kessler's, Strack & Van Til, and ShopRite.
  • The Ideal digital circular doesn't just signify an impressive number of store participation, it symbolizes a shift towards more efficient and impactful digital marketing solutions and an effective alternative to costly print circulars.
  • To learn more about the Ideal digital marketing platform, please contact Adam Zimmerman at [email protected] .

Harmonize Launches ML-powered Employee Lifecycle Management Platform for IT Teams to Streamline and Secure Enterprise Access

Retrieved on: 
Monday, December 4, 2023
Identity, SAN, Organization, IGA, IBM, CSO, MacOS, ChromeOS, Luigi, Intelligence, Automation, Veteran, Linux, Mobile device management, Software, Connective tissue, Harmonization, SSO, CISO, AI, Medical device, Online shopping, Microsoft Windows

SAN FRANCISCO, Dec. 4, 2023 /PRNewswire/ -- Harmonize, the intelligent employee lifecycle management platform for access and compliance, today announced the launch of its platform for CISO, CSO, and IT leaders seeking easier processes to alleviate security risk. Harmonize solves identity lifecycle management with automation using AI and ML models to help SMBs and enterprises save valuable time and cost. The software plugs the gaps in identity management by automating entitlement analysis to provide more contextual insights for decision-making by the IT and security admins. Harmonize is the connective tissue using employee data to make intelligent decisions, replacing a traditionally manual process for access requests.

Key Points: 
  • Harmonize solves identity lifecycle management with automation using AI and ML models to help SMBs and enterprises save valuable time and cost.
  • Harmonize is the connective tissue using employee data to make intelligent decisions, replacing a traditionally manual process for access requests.
  • Integrating Harmonize as an employee lifecycle management platform allows small businesses and medium-sized enterprises to do more with less.
  • Mobile Device Management: Powered by Fleet Device Management, Harmonize MDM seamlessly integrates with the employee lifecycle providing features like "Lock device at time of offboarding".

Eurasia Group Foundation Announces New Name for a New Era: Institute for Global Affairs

Retrieved on: 
Tuesday, November 28, 2023
Global Affairs Canada, Policy, IGA, Student, Multimedia, EGF, Education Action Group Foundation, Public opinion, Eurasia Group, Education, Management

NEW YORK, Nov. 28, 2023 /PRNewswire-PRWeb/ -- The Eurasia Group Foundation (EGF), a leading nonprofit dedicated to helping people understand the everyday impact of global events, has announced its new name: Eurasia Group Institute for Global Affairs (IGA). The organization remains steadfast in its commitment to amplify voices underrepresented among foreign policy professionals and promote civic engagement on today's most pressing global challenges. It also remains committed to exploring approaches to US foreign policy better tailored to new global realities and the preferences of American voters. Board president and founder Ian Bremmer reflected, "I've spent my whole professional life trying to help people understand the dynamics which shape – and reshape – our world. This has been the goal that, in different ways, we pursue at Eurasia Group, GZERO Media, and the public-facing analysis and education work at the nonprofit, Eurasia Group Institute for Global Affairs."

Key Points: 
  • Eurasia Group Foundation unveils new name, logo, and look, reflecting its global education mission and dedication to increasing public engagement with global affairs.
  • NEW YORK, Nov. 28, 2023 /PRNewswire-PRWeb/ -- The Eurasia Group Foundation (EGF), a leading nonprofit dedicated to helping people understand the everyday impact of global events, has announced its new name: Eurasia Group Institute for Global Affairs (IGA).
  • It also remains committed to exploring approaches to US foreign policy better tailored to new global realities and the preferences of American voters.
  • This has been the goal that, in different ways, we pursue at Eurasia Group, GZERO Media, and the public-facing analysis and education work at the nonprofit, Eurasia Group Institute for Global Affairs."

New Report Shows 95% of CISOs, CSOs and CIOs Fear Identity-related Threats

Retrieved on: 
Thursday, November 16, 2023
Risk, Administration, Identity Governance Framework, Organization, IGA

COPENHAGEN, Denmark, Nov. 16, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today released its State of Identity Governance Report 2024, examining the IT and business leaders' perspectives on identity threats and solution choices. The report is available for download at link.

Key Points: 
  • The report is available for download at link .
  • As digital transformation and hybrid work converge, identity and access management procedures have become more complex.
  • A successful approach to identity governance must strike a balance between enhancing an organization's security and facilitating business agility in the context of end-user workflows.
  • For a deeper look at insights unveiled by the data, register for Omada's webinar, Decoding the State of IGA, here.

New Report Shows 95% of CISOs, CSOs and CIOs Fear Identity-related Threats

Retrieved on: 
Thursday, November 16, 2023
Risk, Administration, Identity Governance Framework, Organization, IGA

COPENHAGEN, Denmark, Nov. 16, 2023 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today released its State of Identity Governance Report 2024, examining the IT and business leaders' perspectives on identity threats and solution choices. The report is available for download at link.

Key Points: 
  • The report is available for download at link .
  • As digital transformation and hybrid work converge, identity and access management procedures have become more complex.
  • A successful approach to identity governance must strike a balance between enhancing an organization's security and facilitating business agility in the context of end-user workflows.
  • For a deeper look at insights unveiled by the data, register for Omada's webinar, Decoding the State of IGA, here.

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

Retrieved on: 
Thursday, November 9, 2023
FRSC, Psoriasis, MD–PhD, Patent, Composition of matter, SFA, TB, Cytokine, FRCPC, University, Research, Psoriasis Area and Severity Index, Conditional sentence, IGA, Disease, Cancer, Autoimmune disease, OC, Infection, Safety, Therapy, Patient, PASI, Immunosuppression, Toxic leukoencephalopathy, Pharmaceutical industry

Additional participants in this raise were the Ben Franklin Technology Partners of Pennsylvania, Savantus Ventures and Asymmetry Ventures.

Key Points: 
  • Additional participants in this raise were the Ben Franklin Technology Partners of Pennsylvania, Savantus Ventures and Asymmetry Ventures.
  • SFA-002 is an oral pill that simultaneously acts on multiple therapeutic pathways, unlike other drugs on the market which target a single channel.
  • SFA Therapeutics is also pleased to announce that North South Ventures Managing Partner, Dr. David Naylor, MD/PhD, OC, FRCPC, FRSC, has joined SFA Therapeutics’ Board of Directors.
  • Psoriasis is an incurable chronic disease that affects 125 million people worldwide, with the global psoriasis treatment market size projected to grow at a CAGR of 9.2%.

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

Retrieved on: 
Sunday, November 5, 2023
Survival, Patient, KIT, WCI, Social isolation, PN, Itch, Neuron, B cell, Skin, Conference, Sleep, Bleeding, Abstract (summary), CQD, Quality of life, Neuroinflammation, IGA, Prurigo nodularis, Disease, Hives, Depression, Safety, Anxiety, Mast cell, Therapy, Pain, Conference call, Vaccine, Pharmaceutical industry, Dermatology

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN. This study is the first to demonstrate that barzolvolimab, a mast cell depleting agent, can potentially be used to treat PN and other chronic itch indications. The data will be presented in an oral presentation during the “Hot Topics” Session at the 12th World Congress on Itch (WCI) 2023 on Tuesday, November 7th by Martin Metz, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin. Abstracts accepted for presentation at the meeting were released today.

Key Points: 
  • - Conference call to be held on Monday, November 6th at 8:00 am ET to discuss study results -
    HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
  • Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN.
  • This study is the first to demonstrate that barzolvolimab, a mast cell depleting agent, can potentially be used to treat PN and other chronic itch indications.
  • The Phase 1b double-blind, single intravenous (IV) dose study randomized 24 adults (evaluable: n=23 safety; n=22 efficacy) with moderate to severe PN across three arms: (1) barzolvolimab 3.0 mg/kg (n=9), barzolvolimab 1.5 mg/kg (n=7) and placebo (n=8).